The Humostatic Defect in Hemophilia and its Temporary Correction
As an introduction to this discussion on surgery in the himorrhagic states the first thing to 4o is to try to get into perspective the magnitude of the problems they create. Apart from thrombocytopenic purpura these disorders are very uncommon and any one surgeon is unlikely to iave to deal with more than two or three cases it. the course of his career unless he is associated with a specialist centre. Hemophiia is the commanest of the constitutional himorrhagic state; it occurs in only two or three people per 100,OCO of the population but, although there are only a thousand or so severe haemophilic patients inr this country, each of them constitutes an almost continuous and life-long responsibility for his doctors and, from time to time, for the surgeon who has to decide whether or not to operate, usually in circumstances of grave emergency. A few years ago almost any operative surgery in such cases of defective clotting would probably be disast ous and could only be considered as a last resort; ow, because of accurate diagnosis and therapy b sed on the specific replacement ofany missing clo ting factor, the hazards of surgery have been gr atly reduced in most of these cases. The responsi ility has therefore shifted, to some extent, to those o ho can provide the treatment and laboratory ser ices which wiU allow the surgeon to deal with the patient as if he were a person with normal hemostasis.
Before any of these states are discussed in detail, we should consider briefly why they are hiemorrhagic, which means considering why the normal person is not. A large proportion of the circulating lilood is contained in vessels le than 1 mm in diameter, and the normal hTnAostatic mechanism is so efficient in controlling any traumatic bleeding from vessels of this size that its function is often taken for granted. Surgeons often seem to be curiously unaware of what they owe to nature when their ordinary patients do not bleed to death: having made a sizeable incision they clamp or cauterize a few dozen of the larger vessels and really believe that they have done a major part in stopping the bleeding but, for every one of these large vessels which are cut and clamped, many thousands of small ones have been quietly and safely sealed by nature. Lack of appreciation of this is sometimes shown by the reaction of the surgeon in his first encounter with himophilia when he may confidently embark on an operation despite the misgivings of others, not least the patient: he simply cannot believe that his technique is not enough to secure hiemostasis and he is both astonished and dismayed when he finds that it is not. In fact, in such cases all the ordinary himostatic measures are useless or worse than useless, since they often cause more tissue damage. One can no more stop lumophilic bleeding by clamps, cauteries or sutures than one can turn a cotton shirt into a waterproof by sewing up the button holes. Our surgeon's reaction on the next occasion he is faced with a similar problem is often a sort of over-swing and he will refuse to consider any operation, however necessary it may seem to be. Until a few years ago this over-caution was certainly preferable to over-confidence but now it is unjustified in cases in which specific treatment can restore, if only temporarily, hzmostatic efficiency to normal.
The natural hlmostatic mechanism is a most subtle, interlocking combination of three processes, fibrin formation, platelet aggregation and vascular contraction. Almost immediately after vascular injury the platelets adhere to the damaged tissue and to each other to build up a haemostatic plug. In very small vessels theseplatelet plugs may be sufficient to stop bleeding but, in larger ones, they must be reinforced by. ibrin formation if they are to withstand the blood pressure. Vascular contraction is important because it reduces the calibre of the vessel and also helps to consolidate the hrmostatic plug.
The mechanism of platelet aggregation is now the subject of intensive study and a great deal has been learnt during the past few years. It is probable-that platelet adhesion is due -to adenosine diphosphate, which is a powerful platelet agglutinin known to be released in areas of damage and by the platelets themselves if they are exposed to foreign surfaces or the. action of thrombin. The mechanism of vascular contraction is stillnbscure: it may be due to the direct effect of trauma on. the muscle of the vessel wall or to nervous impulses, but it is also due to vaso-active substances released by the platelets and to substances formed in the blood as a result of clotting.
The so-called classical theory of blood clotting postulated that something called thromboplastin activates prothrombin to form thrombin, which acts on fibrinogen to form fibrin. As far as it goes this theory is perfectly sound and it probably applies to some lower animals and perhaps to the blood of our own ancestors 50 million years ago. Thrombin is a proteolytic enzyme which splits the fibrinogen molecule so that it polymerizes to form fibrin; prothrombin is therefore a proenzyme. The trouble comes when one examines the idea of 'thromboplastin' and the process of prothrombin activation. The activator of prothrombin does not normally exist in the blood, it has to be generated before the blooa will clot naturally. This thromboplastin generation can be promoted. by contact of the blood with a foreign surface, or by entry into the blood of enzymes from damaged tissues. The surface contact activation process seems ta be the most important for normal hrmostasis. More and more factors have been discovered to be involved in these processes and confusion was complete until it was decided by an International Committee that they should be known by Roman numerals. We therefore have blood clotting factors I to XII but it is unusual to use numerals for fibrinogen, prothrombin and calcium, so that only V to XII are in common use. Factor XII can be activated by surface contact to yield an enzyme which activates the next proenzyme which activates the next and so on, in a definite sequence. Fig 1 shows the probable order of reactions following surface contact. I believe that the whole system is a sort of six-stage amplifier; it has probably evolved in this way as a most efficient mechanism for converting the minute stimulus of surface contact into the sudden and powerful response of thrombin formation. There are a few complications which must be mentioned, as they concern hrmostatic efficiency ( Fig 2) . Tissue damage releases enzymes which activate Factor X via the activation of Factor VII, but this does not appear to be a very efficient system on its own. Platelets are required for efficient clotting because during their aggregation they provide a phospholipid catalyst. They do this under the influence of thrombin so that the two processes of clotting and platelet aggregation are interlocked in both directions. SURFACE From the present point of view, the most important fact is that each one of these clotting factors may be deficient as the result of hereditary defects, of disease or of the action of drugs. The most important of these deficiency states are hemophilia, which is a hereditary deficiency of Factor VIII, and Christmas disease which is a deficiency of Factor IX. The other natural deficiencies are much less common. Apart from these constitutional clotting disorders, liver disease may reduce prothrombin and Factors VII and X, as also, naturally, will the use of the anticoagulant drugs of the dicoumarin type. Other types of hkmostatic defect may arise from abnormalities or deficiency of the platelets or abnormal vessels.
Our own interest in Oxford has been mainly in himophilia and its treatment, but a great deal of what we have been able to learn also applies to the specific diagnosis and treatment of other types of clotting defect. Hemophilia is due to a defective gene on the X chromosome causing a deficiency of Factor VIII, which can be complete or partial so that there are grades of severity in different families. Now that Factor VIII can be measured quantitatively one can observe the effect on htmmostasis of these various grades of deficiency. Table 1 shows the haemorrhagic symptoms associated with different observed levels of Factor VIII. If the level is between 50 % and 25 % of normal, the patient usually has no trouble unless he suffers major trauma; the fact that minor injuries do not bleed abnormally at this level whereas larger ones do confirms what one would expect, that hemostatic function is quantitative and that what is enough for small wounds may not be enough for large ones. At levels between 10 % and 25 %, more serious bleeding occurs after even minor injuries; below 10% bleeding into muscles and joints may take place, sometimes apparently spontaneously. It is worth mentioning here that the blood coagulation time as ordinarily measured is normal with Factor VIII levels above about 1-2 %, though clotting A unit of Factor VIII is the average amount in 1 ml of normal plasma. The maximum practical dose-volume (column 3) determines the maximum blood level (as a percentage of normal) which can be obtained efficiency may be greatly impaired. The really severe haemophiliac usually has 0% Factor VIII and he soon becomes crippled by haemarthroses and other tissue hemorrhages: it can be seen, therefore, that if the blood level of Factor VIII could be raised to 25 % of normal serious bleeding from all but the severest injuries could be prevented.
By the intravenous injection of various preparations one can raise the blood level of Factor VIII, though the effect is short lived. Table 2 shows the different preparations which contain Factor VIII and its concentration in units, a unit being the average amount of Factor VIII in 1 ml of normal plasma. Fresh whole blood and plasma have relatively low concentrations of Factor VIII and these are usually diluted by citrate solution. Since one cannot give more than a certain volume without overloading the circulation, only a limited blood level can be attained. The last column in Table 2 shows the maximum blood level one is likely to achieve, which for whole blood will be less than 10% and for plasma not more than 20 %. If higher levels are required, as they often are, then concentrated material must be used. Human antihaemophilic globulin (AHG) is prepared by fractionation laboratories in association with the transfusion service and, as reconstituted for infusion, has a concentration of Factor VIII about four or five times that of normal plasma, so that higher blood levels can be reached. Unfortunately this material is only produced in relatively small quantities and there is not nearly enough to go round for all the purposes for which it is suitable. The last preparation shown in Table 2 is animal AHG derived from ox or pig blood, which is available in virtually unlimited quantities. It can be made up for infusion at high concentrations but 10-15 units per ml is a usual figure: enough can be given to produce blood levels of 100% or more, provided that the patient has not developed antibodies or inhibitors. The main objection to this material is that, being a foreign protein, it is antigenic; injections of the same preparation in the same patient can be given only for a limited time, usually ten to fourteen days, since he then tends to develop resistance, with a loss of therapeutic effect and probably allergic reactions. A further course of a different animal preparation can be used to follow on if necessary, so that about three weeks of effective hemostatic treatment can be obtained if the two preparations are used, usually long enough to allow healing to be complete after major surgery or injury. Having had this animal AHG, it it probably unsafe for the same patient to have a second course of the same material at a future date because of the risk ofanaphylaxis. Animal AHG is therefore reserved for the treatment of serious emergencies only.
In considering the doses of these materials required to ensure an effective cover for surgery or to prevent bleeding from an accidental injury, one has to allow for the fact that the half-life of injected Factor VIII in the body is only about twelve hours; therefore twenty-four hours after an injection the blood level will be down to a quarter of its immediate post-injection level. Since, in practice, it is seldom feasible to give infusions of these materials more often than once in twenty-four hours, though in emergencies it may have to be done, it is this twenty-four-hour level which may determine the hemostatic efficiency achieved. Fig 3, The figures in brackets in column 2 indicate the levels at twentyfour hours after the immediate post-infusion level. Column 3 indicates the dose required to achieve these levels, and the type of material usually employed illustrates the maximum and minimum blood levels achieved with different doses of plasma and concentrated materials: only with high doses of animal AHG is it possible to keep the blood levels above 25 % for the whole of the twenty-four-hour period.
From these figures and from our own experience with 47 major operations and scores of minor and dental operations in htmophilia, it is possible to define the therapeutic requirements needed for various surgical procedures. Bleeding which cannot be controlled by the usual mechanical methods of hamostasis is one of the most alarming accidents that can befall a surgeon. It is also one that brings home to us our dependence on the normal processes of coagulation in our everyday work. Fortunately such misfortunes are rare and they can usually be avoided.
Careful questioning should elicit a history of bruising or of abnormal bleeding after tooth extraction but this information may sometimes be withheld unless specifically asked for. Where any such suspicion of coagulation defects is raised it should be pursued before surgery is undertaken, for replacement therapy may make operation safe.
What tests should a surgeon instigate in these circumstances? A platelet count, the bleeding time, the clotting time and the one-and two-stage prothrombin estimations are the usual ones but they are not always enough. The clotting time in hiemophilia may be deceptive. A clumsy venepuncture, especially in a difficult, frightened child, may decrease the-observed clotting time to within normal limits by the addition to the blood of tissue enzymes; such a reading will give a completely false impression of the safety of operation. Furthermore the clotting time in hemophilia is not -prolonged until the level of antihmmophilic globulin (AHG) falls below 1 % in the plasma and major surgery is dangerous when the level is less than 25 %. As there are moderate, bad and worse hlemophiliacs according to the amount of AHG naturally present, it is necessary that the amount present in each patient should be estimated before operation is undertaken if the laboratory is equipped to do this. Such an estimation takes about two hours and, when the condition of the patient is desperate, as for example from a bleeding peptic ulcer, the time can be usefully employed by transfusion of fresh whole blood or plasma. If the laboratory is not equipped to assay AHG the thromboplastin generation test should be done, which takes about one hour.
The estimation of the bleeding time may not always be reliable. In Von Willebrand's disease, for example, this test may show phasic variations and the seriousness of the condition may be greatly affected by an associated AHG deficiency. The treatment of such AHG deficiency is easier than that in htmophilia because the AHG injected is used up more slowly and the injections can be given at longer intervals without the plasma level falling below the base line of 25 %. There is also a suggestion in this disease that bleeding is more likely to occur from mucous membranes than from skin or muscle. It may sometimes be reasonable to make a preliminary incision at the site of operation and to sew it up and wait to see if bleeding occurs. We have done this in one patient who had a coarctation of the aorta: a left thoracotomy incision was made through the skin and the latissimus dorsi muscle and sutured without opening the pleura. As this incision healed perfectly it was reopened a few days later and the coarctation resected successfully.
Anticoagulants and Surgery Numbers of patients are now being treated on 'life-long anticoagulant therapy' for coronary thrombosis, mitral stenosis, chronic pulmonary embolus and thrombophlebitis; it is inevitable that some of these patients will present themselves from time to time for operation. So long as the prothrombin level is not below 20 % major surgery can be undertaken with safety but the level should be checked carefully in the postoperative period to avoid too great a variation.
When anticoagulants of the dicoumarol group are stopped suddenly there is a tendency to an overswing toward vascular thrombosis; if this coincides with an extensive and prolonged opertifie procedure the tendency to thrombosis
